Elanco Beats and Falls, Zoetis Cuts and Recovers: Animal Health’s Contrary August

August 2026 delivered a month in which good news was punished and bad news absorbed. Elanco raised full-year guidance for the third consecutive quarter and finished the month as the sector’s worst performer, down 7.4%, while Zoetis cut revenue guidance by more than $500 million and ended August marginally higher. Only Virbac closed the month with a meaningful gain, leaving the listed animal health sector broadly flat to negative despite a heavy run of earnings beats.

Elanco was the month’s paradox. Q2 revenue of $1.37 billion was up 10% reported and 8% organic, Zenrelia reached blockbuster status, Credelio Quattro passed 50% US clinic penetration, and full-year guidance was lifted to $5.09–$5.14 billion with adjusted EPS raised to $1.10–$1.16. UBS subsequently raised its price target to $33 from $31 with a Buy rating, and the company completed a 25,000 sq ft monoclonal antibody manufacturing expansion at Elwood on 26 August. Yet the stock fell from $26.37 to around $24.41 , profit-taking after a twelve-month run that had taken shares from a 52-week low of $17.11 to a high of $27.98.

Zoetis told the opposite story. Q2 revenue was flat at $2.5 billion, adjusted EPS of $1.87 marginally beat, but full-year revenue guidance was cut to $9.12–$9.32 billion from $9.68–$9.96 billion and adjusted EPS to $6.15–$6.25. William Blair downgraded to Market Perform on worse-than-expected dermatology declines and continued Simparica Trio share loss. Institutional flows were split: Wellington Management cut its stake 7.2%, selling 726,201 shares, while VanEck added 303,395 shares. The stock nonetheless closed 28 August at $77.34, ending the month broadly flat after a late recovery. Jay Saccaro joined as CFO and COO on 17 August.

Phibro beat expectations, gapping up to open at $39.39 before settling back to $36.28 , a reminder that the Zoetis medicated feed additive acquisition, which added 37 product lines and operations in 80 countries, has lifted revenue 21% but left cash generation still catching up.

Virbac was the sector’s steadiest performer, trading in the €323–€325 range in late August on the back of H1 revenue growth of 7.4% at constant exchange rates and confirmed full-year guidance.

Vetoquinol drifted near its 52-week low with H1 results not due until September.

Ourofino reported 30.7% revenue growth but a 33.3% fall in adjusted net profit on manufacturing provisions. Eco Animal Health traded thinly with no material news.

Among the private majors, Merck Animal Health delivered $1.78 billion in Q2 revenue, up 8%, while Boehringer Ingelheim acquired Swiss equine biotech Evax AG , neither publishes a share price.